A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
- Conditions
- DepressionMajor Depressive DisorderInsomniaMDD
- Interventions
- Drug: Placebo
- Registration Number
- NCT02669030
- Lead Sponsor
- Institute for Advanced Medical Research, Alpharetta, GA
- Brief Summary
Depression with ongoing insomnia is a common clinical presentation with patients. Clinical data suggests that patients with insomnia that receive concomitant treatment with a sleep aid experience a more robust antidepressant response along with a quicker response. The purpose of this clinical study is to compare the effectiveness of the FDA-approved insomnia medication suvorexant, also known as Belsomra®, as add-on treatment to an antidepressant to that of placebo plus antidepressant treatment in patients with depression and residual or ongoing insomnia.
- Detailed Description
Many patients with depression suffer from residual insomnia. This study is a six week, randomized, double-blind, placebo-controlled, trial to study suvorexant augmentation of continuing antidepressant therapy against placebo with continuing antidepressant therapy. Patient volunteers must be on a stable antidepressant treatment and will remain on this treatment for the duration of the study. Patient volunteers that qualify and enroll in the clinical trial will either receive suvorexant 10 mg/day and may have it adjusted to a dose of either 15 mg or 20 mg/day. Treatment is for a total of six weeks in addition to a clinical follow-up visit.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 74
- Provide written Informed Consent
- Diagnosis of depression (MDD)
- Currently on antidepressant
- Healthy and/or stable medically
- unwilling to discontinue current use of sedative hypnotics/sleep aids/benzodiazepines or over the counter sleep aids/supplements
- currently using other psychotropics other than antidepressants
- at risk of self harm or a suicide attempt within the past 12 months
- history or presence of psychotic disorders
- known hypersensitivity to suvorexant
- presence of any other sleep disorder other than residual insomnia of depression
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo no augmentation of FDA-approved antidepressant treatment Suvorexant suvorexant suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment
- Primary Outcome Measures
Name Time Method Total Sleep Time Six weeks ( baseline to end of treatment) assessment of total amount of time spent sleeping
- Secondary Outcome Measures
Name Time Method Insomnia Severity Index (ISI) Six weeks ( baseline to end of treatment) assessment of insomnia severity
Sheehan Disability Scale Six weeks ( baseline to end of treatment) assessment of impact of symptoms on performance
Perceived Deficits Questionnaire (PDQ) Six weeks ( baseline to end of treatment) a brief patient-rated scale to assess subjective cognitive dysfunction in people with depression
Hamilton Depression Rating Scale Six weeks ( baseline to end of treatment) assessment fo depressive symptom severity
Wake After Sleep Onset (WASO) Six weeks ( baseline to end of treatment) assessment of amount of time spent awake after initial onset of sleep
Sleep Latency (SL) Six weeks ( baseline to end of treatment) assessment of amount of time it takes to fall asleep
Trial Locations
- Locations (2)
Medical College of GA at Augusta Univeristy
🇺🇸Augusta, Georgia, United States
Institute for Advanced Medical Research @ Mercer Univeristy
🇺🇸Atlanta, Georgia, United States